BRM ex-div NAV as at 4/12/24 - $0.7826

MKTUPDTE
Thu, Dec 05 2024 02:24 pm

BRM NAV as at 4/12/24 - $0.7826 (after deducting 1.56cps dividend payable)

Date 4/12/2024 30/11/2024
BRM NAV $0.7826 $0.8002
Share price close $0.71 $0.71
Discount 9% 11%

The above net asset value (NAV) is unaudited and net of fees and tax.

The NAV per share is after deducting an accrual for a 1.56 cents per share dividend to be paid on 20 December 2024. The NAV per share is also calculated after deducting treasury stock of 1,659,308 shares (acquired under the Barramundi buyback programme). A performance fee payable to the Manager is currently being accrued in the NAV calculation.

The five largest portfolio holdings at 4 December 2024 are approximately as follows:

CSL 10%
WiseTech 7%
Seek 6%
Xero 5%
Macquarie 5%


BACKGROUND
Barramundi is a listed investment company that invests in growing Australian companies. The Barramundi portfolio is managed by Fisher Funds, a specialist investment manager with a track record of successfully investing in growth company shares. The aim of Barramundi is to offer investors competitive returns through capital growth and dividends, and access to a diversified portfolio of investments through a single tax-efficient investment vehicle. Barramundi listed on the NZX Main Board on 26 October 2006 and may invest in companies that are listed on an Australian stock exchange or unlisted companies.

Contact
Corporate Manager
Barramundi Limited
Tel +64 9 4840352


Announcement PDF


Markets News

NZ sharemarket continues sliding, down 0.5%
Markets Market close

NZ sharemarket continues sliding, down 0.5%

The S&P/NZX 50 Index closed at 12,692.72, down 68.47 points or 0.54%.

Graham Skellern 12 Dec 2024
Markets

Spark sells remaining Connexa stake for $314m

The sale will result in a $70m gain on telco's books.

Ben Moore 12 Dec 2024
Spark sells remaining Connexa stake for $314m
Primary Sector

Zespri on track for 'moderate increase' in volume next year

Zespri's producer vote to expand global supply passed this week.

Riley Kennedy 12 Dec 2024
Zespri on track for 'moderate increase' in volume next year